Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avicena drug candidate found effective in treatment of Huntington’s disease
The open-label, dose escalation study, which evaluated daily administration of HD-02 in doses ranging from 10 to 40 grams, showed that a 30 gram dose provided the optimal
The open-label, dose escalation study, which evaluated daily administration of HD-02 in doses ranging from 10 to 40 grams, showed that a 30 gram dose provided the optimal
Cefpodoxime Proxetil is a third generation cephalosporin antibiotic which has a broad spectrum activity against organisms causing infectious diseases. With limited generic competition in this product, Orchid hopes
The opinion is primarily based on the results of Reveal and Champion, the two randomized, controlled, multi-center clinical trials in adult patients. In both trials, the signs and
The Prescription Drug User Fee Act action date for both applications is July 27, 2008. The supplemental new drug application (sNDA) seeks an expansion to the approved product
UCB plans to utilise the appeal process to request a Committee for Medicinal Products for Human Use (CHMP)re-examination of the submission. A decision is expected during the first
Prandin (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus. PrandiMet is a combination tablet of repaglinide
Since the most recent update on Miraxion to treat Huntington’s disease (HD) on August 1, 2007, the company has continued a comprehensive analysis of all clinical data with
The Tortuous Tracker Delivery System (TT) is designed to simplify stent graft implants by requiring reduced deployment force, providing the physician with increased control over placement of the
Schering-Plough said that the acquisition created a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Organon BioSciences is comprised
The approval is based on data from two clinical trials involving more than 1,200 patients with moderate or severe high blood pressure. In the trials, Avalide (irbesartan-hydrochlorothiazide) -treated